(P017) Long-Term Biochemical Progression-Free Survival and Quality-of-Life Outcomes in a Single-Institution Cohort of Prostate Cancer Patients Treated by Real-Time Inversely Optimized Prostate Seed Implantation
Overall, inversely optimized low-dose-rate prostate seed implantation, resulting in reduced needle and source exposure, demonstrates excellent, durable biochemical progression–free survival with modest grade 2 GU and very low GI toxicity in selected low-risk and favorable intermediate-risk patients.
Eric Kemmerer, MD, Abhirup Sarkar, MS, James Martelli-Raben, Tate Muratori-Levit, Hungcheng Chen, MS, Firas Mourtada, PhD, Adam Raben, MD; Department of Radiation Oncology, Drexel University; Department of Radiation Oncology, Christiana Care
PURPOSE: Inversely optimized low-dose-rate prostate seed implantation (IO-PSI) has been shown to offer excellent biochemical progression–free survival (bPFS), with a favorable toxicity profile. Here, we report 9-year outcomes in patients with low-risk or intermediate-risk (IR) prostate cancer and examine for correlates of biochemical control and genitourinary quality-of-life (GU-QOL) outcomes.
METHODS: From 2003–2015, a total of 492 patients were identified who had received real-time IO-PSI as definitive treatment for prostate cancer, 353 with at least 2 years of follow-up. The median pretreatment prostate-specific antigen level was 5.1; median dose was 145 Gy (96% via 125I); 91% were T1c; and 74%, 21%, and 4% had low-risk, favorable IR, and unfavorable IR disease, respectively. Seven percent received short-term androgen deprivation (SAD). Four patients had high-risk prostate cancer and were excluded from the survival analysis (Kaplan-Meier analysis with log-rank testing) for n = 349 patients. Cox proportional hazards and multivariable regression were performed to examine the relationship of clinical and dosimetric variables with bPFS and GU-QOL. ANOVA (analysis of variance) was used to compare dosimetry by risk group (P < .05).
RESULTS: At a median follow-up of 40 months, the overall 9-year bPFS was 92%, with 95%, 83%, and 75% in the low-risk, favorable IR, and unfavorable IR groups, respectively (P = .0002). Outcomes for men with Gleason 3/4 and 4/3 bPFS did not differ (P = .92). No significant difference in dosimetry among risk groups was observed. On Cox proportional hazards analysis, only risk group correlated with bPFS (P = .001). On multivariable analysis, postimplant V150% correlated with GU-QOL score (P = .0009). Crude incidences of grade ≥ 2 GU and gastrointestinal (GI) toxicities were 25% and 1%, respectively. No benefit to SAD was observed.
CONCLUSION: Overall, IO-PSI, resulting in reduced needle and source exposure, demonstrates excellent, durable bPFS with modest grade 2 GU and very low GI toxicity in selected low-risk and favorable IR patients. Unfavorable IR outcomes warrant further investigation of dose-escalation strategies. Risk group and postimplant V150% correlate with bPFS and postimplant GU-QOL score, respectively.
Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
